What's Happening?
Vivos Inc., a medical device company known for its RadioGel® Radionuclide Therapy™, is set to open new production facilities in the U.S. and internationally. The company has secured a production space at the Applied Process Engineering Laboratory in Richland, Washington, and is in discussions with radiopharmaceutical manufacturers in India for an international site. These facilities aim to enhance production capacity and efficiency, supporting the global expansion of Vivos' therapies. The U.S. facility will focus on automated production development, while the international site is expected to reduce shipping costs and logistical complexities.
Why It's Important?
The expansion of Vivos Inc.'s manufacturing base is a strategic move to support its growth in the medical
device industry. By establishing a domestic and international production footprint, the company aims to increase its production volumes and improve operational efficiency. This expansion is crucial for meeting the growing demand for its RadioGel® and IsoPet® therapies, both in the U.S. and globally. The international facility, in particular, is expected to facilitate access to new markets and reduce costs, thereby enhancing the company's competitive position in the radiopharmaceutical sector.
